NOW FDA APPROVED FOR COLORECTAL CANCER (CRC) SCREENING

Downloadable resources

Back to Resources
card-image
Email Template

This email template can be used to inform patients you are a Shield account and offer new options for colorectal cancer screening.

Download
card-image
Provider’s Brochure

Complete prescribing information: Read up on everything Shield—including patient eligibility and study details

Download
card-image
New England Journal of Medicine Study on Shield: A Blood-Based Colorectal Cancer Screening Test

This peer-reviewed study published in The New England Journal of Medicine examines the effectiveness of Shield, a blood-based colorectal cancer screening test. It highlights Shield’s accuracy, convenience, and patient-preference benefits, reinforcing its potential as a viable alternative to traditional screening methods

Read the full study
card-image
Patient Fact Sheet

Learn about why screening for CRC is so important and how Shield can help

Download
card-image
Shield Brochure

Provide your patients with additional information on screening with the Shield blood test

Download

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is indicated for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stage II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not indicated for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Provider Brochure for complete product information about the Shield test including full safety information.